Tavapadon as Adjunctive Therapy for Parkinson Disease - TEMPO-3 Trial

The provided sources detail phase 3 clinical trial results for tavapadon, a novel, once-daily dopamine D1/D5 receptor agonist designed to treat Parkinson disease. In the TEMPO-1 study, fixed doses of the medication significantly improved motor function and daily living experiences for patients in the early stages of the disease. Simultaneously, the TEMPO-3 trial demonstrated that tavapadon effectively increases "good-on-time" and reduces daily "off-time" when used as an add-on therapy for patients experiencing fluctuations while on levodopa. Researchers observed that the drug's selective targeting of specific receptors aims to minimize the side effects, such as hallucinations or impulse control issues, often linked to traditional dopamine agonists. Across both studies, tavapadon maintained a favorable safety profile, with most adverse events being mild to moderate in severity. These findings suggest that tavapadon offers a clinically meaningful new option for managing symptoms throughout different phases of the condition.